Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

NCT07107750 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07107750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07107750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
March 27, 2026
Completion date
May 31, 2032
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic biliary tract cancer, metastatic biliary tract carcinoma